There are currently more than ten phase I/II ongoing clinical trials evaluating PSMA-TAT as a single agent in prostate cancer in different settings and with various radiopharmaceuticals (https://clinicaltrials.gov, https://euclinicaltrials.eu). The gene discussed is FOLH1; the disease is Familial prostate cancer.